Adipotide and AOD-9604 Interaction
Adipotide and AOD-9604 have an interaction requiring monitoring for interaction with 90% confidence. No published data on combined use or pharmacodynamic interaction. Both compounds affect the gi tract, so monitoring these systems is recommended.
Compound Profiles
Adipotide
Prohibitin-Targeting Peptidomimetic | Experimental Anti-Obesity
CKGGRAKDC ligand homes to prohibitin/annexin A2 on white-fat endothelium; linked D-(KLAKLAK)2 disrupts mitochondrial membranes post-internalization, triggering localized endothelial apoptosis and adipocyte loss..
View full profileAOD-9604
Modified hGH Fragment | Fat Loss Peptide
Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation, without binding to the GH receptor. Does not affect glucose metabolism or increase IGF-1 levels.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take Adipotide with AOD-9604?
Yes, but with caution. No published data on combined use or pharmacodynamic interaction. Regular monitoring is advised.
Is Adipotide and AOD-9604 safe together?
Based on documented research, this combination is considered monitor. However, shared safety flags include: teratogenic. Monitor accordingly.
What are the interactions between Adipotide and AOD-9604?
No published data on combined use or pharmacodynamic interaction. This assessment has 90% confidence and is based on documented research data.
How should I time Adipotide and AOD-9604?
Adipotide has a half-life of Not established and AOD-9604 has a half-life of 3-4 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.